European Commission Approves Kalydeco for Children as Young as Six Months

European Commission Approves Kalydeco for Children as Young as Six Months
0
(0)

The European Commission has approved a label extension for Kalydeco (ivacaftor), allowing the therapy to be used in infants with cystic fibrosis (CF) who are between the ages of six months and one year.

The decision follows a positive opinion on Kalydeco, marketed by Vertex Pharmaceuticals, that was issued by the Committee for Medicinal Products for Human Use (CHMP) in October.

CF is caused by mutations in the gene CFTR (cystic fibrosis transmembrane conductance regulator), which encodes for a protein also named CFTR. When it functions properly, the CFTR protein acts like a gate on a cell’s membrane, allowing certain charged particles, or ions, to pass in and out.

Some CF mutations can cause the CFTR protein to “stick closed”; Kalydeco works by helping keep the ion “gate” open longer so that the protein can function properly.

In Europe, Kalydeco has been approved for people with CF, ages 12 months and older, who have at least one of nine specific mutations. These mutations are G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R.

In CF patients ages 18 and older, Kalydeco treatment is approved for an even greater number of mutations — 38 in total, including the R117H mutation.

The label extension now granted approves Kalydeco use in people with CF who are at least six months old, and have at least one of the nine mutations for which the treatment is approved among those under age 18. Children eligible for Kalydeco therapy also need to weigh at least 5 kg (about 11 pounds).

The approval for this younger patient population is based largely on the results of the Phase 3 clinical trial ARRIVAL (NCT02725567), which is evaluating Kalydeco in children younger than 2. The trial is still ongoing, but interim results have suggested that Kalydeco can be beneficial for this age group, with a safety profile in line with what has been seen in studies with older children and adults.

“Today’s approval is another milestone in our commitment to treat all people with CF as early in life as possible, given manifestations of CF are often present at birth,” Reshma Kewalramani, MD, executive vice president and chief medical officer of Vertex, said in a press release.

“For the first time, children with CF in Europe as young as 6 months with certain mutations now have access to a medicine that treats the underlying cause of their disease,” Kewalramani said.

The U.S. Food and Drug Administration in April 2019 approved Kalydeco‘s use in the United States as a treatment for children with CF ages 6 to 12 months.

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • CF gene therapy study
  • Kalydeco, CF
  • gene therapy and Vertex
  • Orkambi and glucose levels

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?